Pharmaceutical Execs Unleash Fury Over RFK Jr.'s Vaccine Agenda
A group of pharmaceutical executives, including Pfizer CEO Albert Bourla, has expressed their outrage and disappointment over the extreme anti-vaccine agenda being pushed by Health Secretary Robert F. Kennedy Jr.
Bourla, who had previously avoided criticizing the Trump administration, was candid in his remarks, stating that he is "very annoyed," "very disappointed," and "seriously frustrated" with Kennedy's actions. He also claimed that Kennedy's approach has zero scientific merit and is driven by a political agenda.
Kennedy recently announced a mass overhaul of the childhood vaccine schedule, dropping the number of routine recommended vaccinations from 17 to 11. This drastic change bypassed normal scientific review and decision-making processes, and Kennedy claimed it puts the US in line with peer nations.
However, an analysis by Stat News found that the US is now an outlier, recommending significantly fewer vaccines than many other countries. Leading medical groups, including the American Academy of Pediatrics, are preparing a legal challenge to block the changes.
Pharmaceutical executives are concerned about the impact of Kennedy's rhetoric on vaccine coverage rates and the potential for lawsuits against drug makers. Noubar Afeyan, co-founder and chairman of Moderna, maker of mRNA vaccines, warned that "tomorrow it's everything," implying that the pushback against vaccines will escalate beyond childhood immunizations.
Sanofi Chief Executive Paul Hudson expressed a similar pessimistic outlook, stating that flu vaccination rates are unlikely to increase in the US due to anti-vaccine rhetoric. Bourla also worried about the conditions Kennedy is creating to attack drug makers, citing the potential for "plaintiffs' playbook" and lawsuits against vaccine makers.
The pharmaceutical executives' comments come as the US is experiencing a bad flu season, and the anti-vaccine rhetoric is hitting seasonal flu shots. The midterms are approaching, and many expect that the pushback against vaccines will continue beyond Kennedy's term in office.
A group of pharmaceutical executives, including Pfizer CEO Albert Bourla, has expressed their outrage and disappointment over the extreme anti-vaccine agenda being pushed by Health Secretary Robert F. Kennedy Jr.
Bourla, who had previously avoided criticizing the Trump administration, was candid in his remarks, stating that he is "very annoyed," "very disappointed," and "seriously frustrated" with Kennedy's actions. He also claimed that Kennedy's approach has zero scientific merit and is driven by a political agenda.
Kennedy recently announced a mass overhaul of the childhood vaccine schedule, dropping the number of routine recommended vaccinations from 17 to 11. This drastic change bypassed normal scientific review and decision-making processes, and Kennedy claimed it puts the US in line with peer nations.
However, an analysis by Stat News found that the US is now an outlier, recommending significantly fewer vaccines than many other countries. Leading medical groups, including the American Academy of Pediatrics, are preparing a legal challenge to block the changes.
Pharmaceutical executives are concerned about the impact of Kennedy's rhetoric on vaccine coverage rates and the potential for lawsuits against drug makers. Noubar Afeyan, co-founder and chairman of Moderna, maker of mRNA vaccines, warned that "tomorrow it's everything," implying that the pushback against vaccines will escalate beyond childhood immunizations.
Sanofi Chief Executive Paul Hudson expressed a similar pessimistic outlook, stating that flu vaccination rates are unlikely to increase in the US due to anti-vaccine rhetoric. Bourla also worried about the conditions Kennedy is creating to attack drug makers, citing the potential for "plaintiffs' playbook" and lawsuits against vaccine makers.
The pharmaceutical executives' comments come as the US is experiencing a bad flu season, and the anti-vaccine rhetoric is hitting seasonal flu shots. The midterms are approaching, and many expect that the pushback against vaccines will continue beyond Kennedy's term in office.